Paclitaxel Administered over 3 h Followed by Cisplatin in Patients with Advanced Head and Neck Squamous Cell Carcinoma: A Clinical Phase I Study

Tassilo Schilling,Bernhard Heinrich,Reinhardt Kau,Michael Herzog,Stefan Quasthoff,Klaus Diergarten,Johann Rastetter,A.-R. Hanauske

Paclitaxel Administered over 3 h Followed by Cisplatin in Patients with Advanced Head and Neck Squamous Cell Carcinoma: A Clinical Phase I Study

1997

Tassilo Schilling
Bernhard Heinrich
Reinhardt Kau
Michael Herzog
Stefan Quasthoff
Klaus Diergarten
Johann Rastetter
A.-R. Hanauske

We have performed a clinical phase I trial of a combination treatment with paclitaxel given as 3-hour infusion and cisplatin to determine the maximum tolerated dose and the dose-limiting toxicity in p

Keywords:

Pathology
Cancer
Cisplatin
Medicine
Head and neck squamous-cell carcinoma
Maximum tolerated dose
Head and neck cancer
Paclitaxel
Toxicity
Chemotherapy
in patient
epidermoid carcinoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations